← Back to Clinical Trials
Recruiting NCT07136441

NCT07136441 Sciatic Nerve Stiffness Using Two-Sequences of Lower Limb Neurodynamic Testing: A Shear Wave Elastography Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07136441
Status Recruiting
Phase
Sponsor Cairo University
Condition Sciatic Nerve
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2025-08-15
Primary Completion 2026-02-15

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 40 Years
Study Type OBSERVATIONAL
Interventions
Lower Limb Neurodynamic Test (LLNT) with Shear Wave Elastography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2025-08-15 with a primary completion date of 2026-02-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purposes of the study are: 1. To measure differences in Sciatic nerve (SN) stiffness using shear-wave elastography (SWE) during two movement sequences of the lower limb neurodynamic test (LLNT) in low back pain with sciatica. 2. To measure differences in Sciatic nerve stiffness using shear-wave elastography during two movement sequences of the lower limb neurodynamic test in control group. 3. To compare difference in Sciatic nerve stiffness using shear-wave elastography during two movement sequences of the lower limb neurodynamic test between low back pain patients with sciatica and control group.

Eligibility Criteria

Inclusion Criteria: * Thirty participants ranging in age from 25 to 40 years from both genders with a diagnosis of low back pain with radiating leg pain and thirty control group. * The main symptoms are low back pain with unilateral leg pain(sciatica) for 3-12 months for group A. * Patients with lumbar disc herniation (L4-5) with diagnostic imaging as MRI for group A. * Positive straight leg raising are considered for inclusion in the study for group A. * Control group must be free from any symptoms of nerve irritation or compression, with normal neurological examination findings, including reflexes, sensation, negative straight leg raising and motor strength. Exclusion Criteria: * Diabetes mellitus. * Any type of polyneuropathy * Trauma of lumbar spine * Previous history of back surgery * Piriformis syndrome. * Participants with conditions that reduce image quality on US imaging (thick gluteal subcutaneous fat tissue. * Hip joint prosthesis. * Professional athletes (Neto et al., 2024). * Skin infection

Contact & Investigator

Central Contact

Manar Fawzy Mohammed Hussein, M.Sc

✉ manar.fawzy@the.suezuni.edu.eg

📞 +20 120 140 8924

Principal Investigator

Eman Ahmed Abd Elmoez, PhD

STUDY CHAIR

Professor, Cairo university

Frequently Asked Questions

Who can join the NCT07136441 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 40 Years, studying Sciatic Nerve. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07136441 currently recruiting?

Yes, NCT07136441 is actively recruiting participants. Contact the research team at manar.fawzy@the.suezuni.edu.eg for enrollment information.

Where is the NCT07136441 trial being conducted?

This trial is being conducted at Giza, Egypt.

Who is sponsoring the NCT07136441 clinical trial?

NCT07136441 is sponsored by Cairo University. The principal investigator is Eman Ahmed Abd Elmoez, PhD at Professor, Cairo university. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology